Core Insights - Elicio Therapeutics is hosting a virtual KOL event on June 25, 2025, to discuss the treatment landscape for mutant-KRAS driven pancreatic ductal adenocarcinoma, highlighting the significant unmet medical need in this area [1][2] Company Overview - Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, particularly mKRAS-positive pancreatic and colorectal cancers [8] - The company aims to leverage its proprietary AMP technology to create effective off-the-shelf vaccines, enhancing the education and activation of cancer-specific T cells [8][11] Product Pipeline - Elicio's lead product candidate, ELI-002, is an AMP-powered therapeutic vaccine targeting mKRAS-driven cancers, currently in a randomized Phase 2 trial for adjuvant treatment of PDAC [2][9] - ELI-002 has shown promising results in earlier studies, with a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for the full study population [8] - The company plans to expand ELI-002's application to other mKRAS-positive cancers, including lung cancer [8][10] Technology Platform - Elicio's AMP platform is designed to deliver immunotherapeutics directly to lymph nodes, potentially enhancing immune responses compared to conventional therapies [11][12] - The platform has demonstrated the ability to engage lymph nodes specifically, driving therapeutic immune responses of increased magnitude and durability in preclinical models [11][12]

Core Insights - Elicio Therapeutics is progressing towards an interim analysis focused on disease-free survival in the Phase 2 AMPLIFY-7P clinical trial, expected in Q3 2025, which is a significant milestone for the company and patients with pancreatic ductal adenocarcinoma [1][2] - The company has aligned with the FDA on key design elements for a planned Phase 3 study of ELI-002, indicating regulatory support for its development [1][8] - Elicio's current cash position of $18.4 million is expected to support operations into Q4 2025, beyond the anticipated interim analysis [6][7] Financial Performance - Research and development expenses for Q1 2025 were $7.8 million, a slight increase from $7.6 million in Q1 2024, primarily due to clinical trial costs [4] - General and administrative expenses rose to $3.0 million in Q1 2025 from $2.7 million in Q1 2024, attributed to higher compensation and benefits [5] - The net loss for Q1 2025 was $11.2 million, compared to $11.8 million in Q1 2024, with a net loss per share of $0.87, down from $1.15 in the previous year [6][10] Clinical Development - ELI-002 is being studied as a potential treatment for mKRAS-driven tumors, with the upcoming interim data readout in PDAC seen as a critical validation opportunity for the AMP platform [2][8] - The company plans to finalize the pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in the second half of 2025 [8][19] - Elicio's AMP technology aims to enhance the immune response against cancer by delivering antigens directly to lymph nodes, which may lead to improved therapeutic outcomes [16][17] Corporate Updates - In March 2025, Elicio appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, indicating a strengthening of its leadership team [8] - The company raised $10 million through a registered direct offering of common stock and warrants in January 2025, bolstering its cash position [8]